scholarly journals Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

2020 ◽  
Vol 52 (4) ◽  
pp. 669-681 ◽  
Author(s):  
Matthew Bohm ◽  
Ronghui Xu ◽  
Yiran Zhang ◽  
Sashidhar Varma ◽  
Monika Fischer ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Antagonist Therapy ◽  
Tumour Necrosis Factor Antagonist ◽  
Comparative Safety ◽  
Factor Antagonist ◽  
Necrosis Factor

scholarly journals P356 Infectious events in patients with inflammatory bowel disease: The impact of immunomodulators and tumour necrosis factor antagonist therapy

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S338-S339
Author(s):  
P Andersson ◽  
P Karling
Keyword(s):  
Inflammatory Bowel Disease ◽  
Combination Therapy ◽  
Tumour Necrosis Factor ◽  
Bowel Disease ◽  
Tumour Necrosis ◽  
Antagonist Therapy ◽  
Tumour Necrosis Factor Antagonist ◽  
Inflammatory Bowel ◽  
Factor Antagonist ◽  
Necrosis Factor

Abstract Background Immunomodulators (IM) and tumour necrosis factor antagonist therapy (anti-TNF) are effective treatments for inflammatory bowel disease (IBD) but has been associated with an increased risk for infectious diseases. We investigated the frequency of infectious events in patients with IBD and the association of infectious events with concomitant treatment with IM and anti-TNF therapy. Methods We performed a retrospective medical chart review of patients with IBD, 18 to 65 years of age, included in the Swedish Registry of IBD (SWIBREG) and treated in the catchment area of Umeå University Hospital, Sweden. Data were collected from the period January 1, 2006, to January 31, 2019. An infectious event was defined as an outpatient prescription of antimicrobials or a positive diagnostic test for infection. Results Among the 593 included patients (397 patients with UC and 195 patients with CD), 1398 events occurred. The proportion of events that occurred on treatment with corticosteroids, IM, anti-TNF, combination therapy (IM + anti-TNF) and without any immunosuppressive treatments was 8.3%, 35.8%, 17.7%, 10.0% and 47.4%. Of all patients, 60.4% had at least one infectious event, and 29.3% had >0.3 events per year. Compared with patients not receiving immunosuppressive therapy, an event rate of >0.3 per year was more common among those receiving immunomodulator monotherapy or combination therapy (Table), and was more common in patients with Crohn’s disease than ulcerative colitis (35.0% vs. 26.1%, p = 0.022). There were no significant differences in infectious events between patients who had received immunomodulator monotherapy and patients who had received combination therapy. Conclusion We found an increased frequency of infection associated with the use of combination therapy and immunomodulator monotherapy, but no difference between the two treatments.

scholarly journals Screening for latent tuberculosis before tumour necrosis factor antagonist therapy

2015 ◽  
Vol 45 (5) ◽  
pp. 1510-1512 ◽  
Author(s):  
Richard J. Hewitt ◽  
Aran Singanayagam ◽  
Saranya Sridhar ◽  
Melissa Wickremasinghe ◽  
Onn Min Kon
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Latent Tuberculosis ◽  
Antagonist Therapy ◽  
Tumour Necrosis Factor Antagonist ◽  
Factor Antagonist ◽  
Necrosis Factor

Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry

2010 ◽  
Vol 9 (3) ◽  
pp. 175-180 ◽  
Author(s):  
Francesca Bobbio Pallavicini ◽  
Roberto Caporali ◽  
Piercarlo Sarzi-Puttini ◽  
Fabiola Atzeni ◽  
Chiara Bazzani ◽  
...  
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Cancer Development ◽  
Antagonist Therapy ◽  
Tumour Necrosis Factor Antagonist ◽  
Development Analysis ◽  
Factor Antagonist ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document